Nuvation Bio (NUVB) Competitors $3.72 +0.06 (+1.64%) Closing price 10/8/2025 03:59 PM EasternExtended Trading$3.73 +0.01 (+0.38%) As of 10/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. CRNX, PTGX, KYMR, MLTX, AKRO, ADMA, SRRK, MIRM, ACAD, and ZLABShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), Kymera Therapeutics (KYMR), MoonLake Immunotherapeutics (MLTX), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), ACADIA Pharmaceuticals (ACAD), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Its Competitors Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics MoonLake Immunotherapeutics Akero Therapeutics ADMA Biologics Scholar Rock Mirum Pharmaceuticals ACADIA Pharmaceuticals Zai Lab Nuvation Bio (NYSE:NUVB) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends. Does the media refer more to NUVB or CRNX? In the previous week, Crinetics Pharmaceuticals had 5 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for Crinetics Pharmaceuticals and 4 mentions for Nuvation Bio. Crinetics Pharmaceuticals' average media sentiment score of 0.59 beat Nuvation Bio's score of 0.48 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, NUVB or CRNX? Nuvation Bio has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Which has better valuation & earnings, NUVB or CRNX? Crinetics Pharmaceuticals has lower revenue, but higher earnings than Nuvation Bio. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M161.78-$567.94M-$0.63-5.90Crinetics Pharmaceuticals$1.04M4,023.48-$298.41M-$4.11-10.81 Do analysts rate NUVB or CRNX? Nuvation Bio currently has a consensus price target of $7.86, indicating a potential upside of 111.21%. Crinetics Pharmaceuticals has a consensus price target of $74.45, indicating a potential upside of 67.58%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvation Bio is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88Crinetics Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is NUVB or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. Crinetics Pharmaceuticals' return on equity of -32.28% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-1,413.43% -46.14% -36.04% Crinetics Pharmaceuticals N/A -32.28%-29.45% Do institutionals and insiders believe in NUVB or CRNX? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCrinetics Pharmaceuticals beats Nuvation Bio on 9 of the 17 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.25B$3.35B$6.11B$22.02BDividend YieldN/A2.29%5.69%3.60%P/E Ratio-5.9021.5785.4829.86Price / Sales161.78478.85616.9066.03Price / CashN/A47.1237.9224.43Price / Book2.7210.1413.134.64Net Income-$567.94M-$52.31M$3.30B$1.01B7 Day Performance0.40%5.14%4.29%0.44%1 Month Performance11.04%14.68%9.45%3.13%1 Year Performance68.33%30.98%86.64%15.30% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio2.9205 of 5 stars$3.72+1.6%$7.86+111.2%+66.8%$1.25B$7.87M-5.9060Analyst ForecastCRNXCrinetics Pharmaceuticals3.8853 of 5 stars$43.51-5.2%$73.20+68.2%-14.1%$4.32B$1.04M-10.59210Analyst ForecastPTGXProtagonist Therapeutics2.3506 of 5 stars$65.14-3.4%$68.36+4.9%+48.5%$4.19B$434.43M93.06120Analyst ForecastKYMRKymera Therapeutics1.9574 of 5 stars$58.50+4.0%$59.95+2.5%+30.8%$4.02B$47.07M0.00170Analyst ForecastMLTXMoonLake Immunotherapeutics2.9357 of 5 stars$6.24-89.9%$57.00+813.5%-81.7%$3.98BN/A0.002Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeAKROAkero Therapeutics3.7026 of 5 stars$47.62-0.3%$81.14+70.4%+65.2%$3.82BN/A-23.8130Positive NewsAnalyst ForecastADMAADMA Biologics3.6893 of 5 stars$14.70-5.8%$27.67+88.2%-29.4%$3.73B$426.45M17.09530Analyst ForecastSRRKScholar Rock4.648 of 5 stars$38.36-1.0%$46.40+21.0%+31.2%$3.72B$33.19M-13.18140Analyst ForecastInsider TradeMIRMMirum Pharmaceuticals3.3309 of 5 stars$72.85+0.1%$76.50+5.0%+87.2%$3.66B$336.89M-60.21140Positive NewsAnalyst ForecastACADACADIA Pharmaceuticals4.464 of 5 stars$21.32+1.3%$29.12+36.6%+47.4%$3.55B$957.80M16.03510Analyst RevisionZLABZai Lab2.5827 of 5 stars$32.93+4.1%$56.35+71.1%+35.6%$3.53B$398.99M-16.141,869Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Crinetics Pharmaceuticals Alternatives Protagonist Therapeutics Alternatives Kymera Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives Akero Therapeutics Alternatives ADMA Biologics Alternatives Scholar Rock Alternatives Mirum Pharmaceuticals Alternatives ACADIA Pharmaceuticals Alternatives Zai Lab Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
